Slate Medicines Launches with $130 Million Series A Financing to Advance Anti-PACAP Therapies for the Prevention of Migraine and Other Headache Disorders
Slate Medicines, Inc., a privately-held biotech company advancing next-generation therapeutics for headache disorders, today announced the close of a $130 million Series A financing, alongside the in-licensing of SLTE-1009, an anti-PACAP monoclonal antibody licensed from DartsBio Pharmaceuticals (Guangdong), Ltd.
